Von Willebrand disease - phenotype versus genotype: deficiency versus disease

David Lillicrap1

  • 1Department of Pathology and Molecular Medicine, Queen's University, Kingston, Canada. lillicrap@cliff.path.queensu.ca

Thrombosis Research
|May 11, 2007
PubMed

Insights

Von Willebrand disease (VWD) has three main types based on von Willebrand factor (VWF) levels and function. Genetic studies reveal complex molecular causes for VWD subtypes, particularly type 1.

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Von Willebrand disease (VWD) is categorized into three main subtypes: type 1 (partial quantitative deficiency), type 2 (qualitative defects including 2A, 2B, 2M, 2N), and type 3 (near-complete deficiency of von Willebrand factor (VWF)).
  • Subtypes of type 2 VWD involve distinct defects: 2A (low-molecular-weight VWF), 2B (increased platelet binding), 2M (impaired adhesion despite normal VWF size), and 2N (reduced factor VIII binding).
  • Genetic underpinnings for VWD subtypes are increasingly understood, with type 3 linked to null mutations and type 2N to specific missense mutations affecting factor VIII binding.

Purpose of the Study:

  • To explore the association between specific genetic variants of von Willebrand factor (VWF) and the resulting disease phenotype in Von Willebrand disease (VWD).
  • To characterize the molecular pathogenesis of type 1 VWD, highlighting the diverse genetic changes involved.
  • To investigate the complexity of genetic factors contributing to type 1 VWD, including potential involvement of genes beyond VWF.

Main Methods:

  • Classification of VWD into subtypes based on quantitative and qualitative von Willebrand factor (VWF) defects.
  • Analysis of genetic variants, including missense, splice site, and transcriptional mutations, in patients with Von Willebrand disease (VWD).
  • Examination of VWF gene sequences and assessment for multiple variant sequences or absence of detectable changes in affected individuals.

Main Results:

  • Type 3 VWD is associated with mutations leading to a null phenotype, while type 2N VWD results from recessive missense mutations impairing factor VIII binding.
  • Molecular characterization of type 1 VWD reveals a broad spectrum of genetic alterations, with patients often heterozygous for various mutations.
  • In some type 1 VWD cases, multiple variant VWF sequences were identified, and in a significant number, no VWF gene changes were detected, suggesting other genetic factors may be involved.

Conclusions:

  • The genetic basis for Von Willebrand disease (VWD) subtypes is diverse, with specific mutations correlating with distinct phenotypes.
  • The molecular pathogenesis of type 1 VWD is complex, involving a wide range of genetic changes at the VWF locus.
  • The genetic architecture of type 1 VWD likely extends beyond the VWF gene itself, implicating mutations in other genes.

Related Concept Videos

Pleiotropy01:33

Pleiotropy

Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.
Pedigree Analysis01:35

Pedigree Analysis

Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Genetic Lingo01:11

Genetic Lingo

Overview
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism